Regeneron CEO Leonard Schleifer and CSO George Yancopoulos Named EY 2016 National Life Sciences Entrepreneurs Of The Year

Monday, November 21, 2016 General News
Email Print This Page Comment
Font : A-A+

TARRYTOWN, N.Y., Nov. 21, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced

that Leonard Schleifer, M.D., Ph.D., Founder, President and Chief Executive Officer, and George Yancopoulos, M.D., Ph.D., Founding Scientist, President of Regeneron Laboratories and Chief
Scientific Officer, have been named the EY (Ernst & Young) Entrepreneurs Of The Year® 2016 National Award Winners in the Life Sciences category.

The EY Entrepreneur Of The Year Award, a leading business award for entrepreneurs, recognizes leaders and visionaries who demonstrate innovation, financial success and personal commitment as they create and build world-class businesses. A panel of independent judges selected Drs. Schleifer and Yancopoulos from more than 250 regional award recipients.

"Under Len and George's leadership, Regeneron has grown from a tiny start-up into a leading biotechnology company," said P. Roy Vagelos, M.D., Chairman of the Regeneron Board of Directors. "Even now, as the company has grown to over 5,000 employees, Len and George continue to lead with a fierce entrepreneurial spirit and a willingness to do things differently. This spirit has enabled the Regeneron team to bring important medicines to people in need and to advance a promising pipeline of therapies for serious diseases."

To view the full list of this year's winners, please visit: http://www.ey.com/us/en/about-us/entrepreneurship/entrepreneur-of-the-year.

About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

About EY Entrepreneur Of The Year™The EY Entrepreneur Of The Year is the world's most prestigious business award for entrepreneurs. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries. ey.com/eoy

About EYEY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization and may refer to one or more of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

Media Contact at Regeneron:Alexandra Bowie, Tel. 914.847.3407alexandra.bowie@regeneron.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-ceo-leonard-schleifer-and-cso-george-yancopoulos-named-ey-2016-national-life-sciences-entrepreneurs-of-the-year-300366403.html

SOURCE Regeneron Pharmaceuticals, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook